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doi:10.1016/j.ejvs.2011.05.001Abstract Objectives: This article describes the rationale and design of the DECREASE-XIII
trial, which aims to evaluate the potential of esmolol infusion, an ultra-short-acting beta-
blocker, during surgery as an add-on to chronic low-dose beta-blocker therapy to maintain
perioperative haemodynamic stability during major vascular surgery.
Design: A double-blind, placebo-controlled, randomised trial.
Materials & methods: A total of 260 vascular surgery patients will be randomised to esmolol or
placebo as an add-on to standard medical care, including chronic low-dose beta-blockers.
Esmolol is titrated to maintain a heart rate within a target window of 60e80 beats per minute
for 24 h from the induction of anaesthesia. Heart rate and ischaemia are assessed by contin-
uous 12-lead electrocardiographic monitoring for 72 h, starting 1 day prior to surgery. The
primary outcome measure is duration of heart rate outside the target window during infusion
of the study drug. Secondary outcome measures will be the efficacy parameters of occurrence
of cardiac ischaemia, troponin T release, myocardial infarction and cardiac death within 30
days after surgery and safety parameters such as the occurrence of stroke and hypotension.
Conclusions: This study will provide data on the efficacy of esmolol titration in chronic beta-
blocker users for tight heart-rate control and reduction of ischaemia in patients undergoing
vascular surgery as well as data on safety parameters.
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318 E.J. Bakker et al.Only 8% of patients undergoing major vascular surgery have
a normal coronary angiogram.1 Albeit coronary artery
disease (CAD) is asymptomatic in the vast majority of these
patients, the risk of perioperative cardiac mortality and
morbidity is increased.2e7 Major cardiac complications
occur in 2e3.5% of major surgery patients. The predomi-
nant risk factor is CAD, and complications are usually
preceded by a prolonged haemodynamic instability, leading
to myocardial ischaemia and infarction. The pathophysi-
ology of perioperative cardiac events is complex. Haemo-
dynamic instability may lead to coronary plaque rupture,
initiating coronary artery thrombosis, occlusion and
myocardial infarction (type 1 MI).8e10 In the presence of
stable CAD, myocardial oxygen supply/demand mismatch
due to tachycardia and increased contractility, induced by
perioperative catecholamine surge, may lead to myocardial
ischaemia, ST segment depression and type 2 MI.8,11e13
Perioperative myocardial infarction (PMI) is one of the most
important predictors of short- and long-term morbidity and
mortality associated with non-cardiac surgery.14 Therefore,
it is of vital importance to prevent myocardial ischaemia by
providing haemodynamic stability and adequate heart-rate
control throughout the perioperative period.
Beta-blockers are widely prescribed perioperatively for
perioperative heart-rate control. The proposed mecha-
nism of the beneficial effect of beta-blockers consists of
a decreased myocardial oxygen demand by reducing heart
rate and contractility, also resulting in a lengthening of the
diastolic filling period and reduced shear stress.15 Additional
cardioprotective factors are redistribution of coronary blood
flow to the subendocardium and an increase in the threshold
for ventricular fibrillation. Beta-blockers are thought to have
an anti-inflammatory and plaque-stabilising effect, which
might only be achieved after prolonged treatment.16e18
Beta-blocker therapy is recommended in patients with
known ischaemic heart disease (IHD) and for patients
scheduled for high-risk surgery, based on a reduction in
perioperative cardiac mortality and PMI in several
trials.6,19,20 However, this beneficial effect might be offset
by the induction of serious side effects.
In the randomised Perioperative Ischaemic Evaluation
(POISE) trial, metoprolol succinate was initiated shortly
prior to surgery.7 Patients could receive up to 400 mg of
metoprolol succinate on the day of surgery. This regimen
was associated with a decreased risk of PMI and an increase
in overall mortality and stroke.
A factor to be considered when initiating beta-blockers
prior to vascular surgery is the frequent presence of
asymptomatic left ventricular (LV) dysfunction.21 Patients
with LV dysfunction might respond unfavourably to a fixed
dose of beta-blocker. Therefore, beta-blockers are
commonly titrated over a prolonged period of time in
conditions such as hypertension, angina pectoris and heart
failure.22 In the DECREASE I and IV trials, using a regimen of
bisoprolol, titrated for heart rate, initiated 30 days before
surgery, no increased rate of stroke was observed.6,23
A simple approach of chronic low-dose long-acting car-
dioselective beta-blocker therapy titrated for heart rate,
combined with the perioperative use of a short-acting,
easily titratable beta-blocker, can provide superior hae-
modynamic stability. Heart-rate control might be improved
compared to low-dose long-acting beta-blocker mono-therapy, without the adverse effects such as hypotension,
bradycardia, progression of asymptomatic LV dysfunction,
stroke and mortality associated with high-dose long-acting
beta-blockers without titration for heart rate. Low-dose
long-acting beta-blockers can be initiated 1 week prior to
surgery, as titration of long-acting beta-blocker for tight
heart rate control is not mandatory. If low-dose long-acting
beta-blockers cannot be initiated prior to surgery, esmolol
can provide haemodynamic control, although the additional
effect of chronic beta-blocker therapy is lacking.
We propose a randomised, placebo-controlled trial of
esmolol, titrated for heart rate, as an add-on to standard
medical care, including chronic beta-blockade with meto-
prolol succinate. Esmolol is anultra-short-actingbeta-blocker
with a distribution and elimination half-life of 2 and 9 min
and, therefore, easily titratable.24 Esmolol is highly beta-1
selective and has no intrinsic sympathomimetic activity.25
Materials and Methods
Study design and objective
This single-centre, randomised, placebo-controlled study
compares a group receiving esmolol (Brevibloc) as an add-
on to metoprolol succinate versus a group receiving meto-
prolol succinate and placebo. The primary objective is to
assess the efficacy of esmolol versus placebo as an add-on
to standard medical care for target heart-rate control.
Secondary objectives are to assess the efficacy of esmolol
for reducing the occurrence and duration of myocardial
ischaemia and to assess safety parameters. Approval from
the Medical Ethical Committee was obtained. This trial was
registered as NTR2615 on www.trialregister.nl.
Study population
Patients scheduled for major vascular surgery will be
enrolled after providing informed consent, if none of the
exclusion criteria presented in Table 1 is met.
Randomisation, blinding and treatment allocation
The randomisation for active drug or placebo will be per-
formed by the hospital pharmacist in a 1:1 ratio, using
a computer-generated randomisation list. Patient, research
fellow, nursing and medical staff are blinded, with the
exception of the attending anaesthesiologist and intensivist,
for safety reasons.
Preoperative risk evaluation and initiation of
medical therapy
Patients are screened before vascular surgery using the
recently published European Society of Cardiology (ESC)
guidelines on perioperative care.19 In short, patients with
unstable cardiac symptoms and patients with >2 points on
the revised cardiac risk index3 will be sent for additional
cardiac evaluation and treatment if indicated. In all
patients proceeding to surgery, standard medical therapy
will be initiated.
Table 1 Inclusion and exclusion criteria.
Inclusion criteria
Major vascular surgery Open or endovascular Abdominal Aortic Aneurysm repair,
infrarenal aortic occlusive disease repair, open lower limb arterial
reconstruction, open carotid artery repair
Age  18 years
Exclusion criteria
Active bleeding
Untreated left main disease
Active cardiac conditions Unstable angina pectoris, active heart failure,
serious cardiac arrhythmias, symptomatic valvular disease,
myocardial infarction <6 months
Preoperative positive Troponin T
Contraindication for esmolol use
Previous allergy or intolerance for esmolol
Cancer With an expected life expectancy <6 months
Failure to monitor heart rate With continuous 12-lead electrocardiography because
of surgery or baseline electrocardiographic abnormalities
Excessive alcohol abuse
Pregnancy or planning to become pregnant
Failure to provide informed consent
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All patients will be receiving metoprolol succinate accord-
ing to the ESC guidelines on perioperative care.19 Patients
on beta-blocker therapy other than metoprolol succinate
switch to metoprolol succinate 50 mg once daily at the
screening visit. Beta-blocker-naive patients start with
metoprolol succinate 50 mg once daily at the screening visit
at least 1 week prior to surgery. The beta-blocker dose is
adjusted after 7 days of treatment and prior to surgery to
achieve a resting heart rate of 60e70 beats per minute
(bpm) if tolerated. The same dose is continued the day
after surgery.
Statins
Patients on chronic statin therapy will continue medica-
tion, while statin-naive patients will be treated with flu-
vastatin extended release at a dose of 80 mg once daily.
Aspirin
All patients are on perioperative aspirin therapy, 80 mg
daily, according to recommendations in the American Heart
Association / American College of Cardiology guidelines on
peripheral arterial disease.26
Angiotensin-converting enzyme inhibitors
Patients on chronic therapy will continue their medication.
When LV dysfunction (left ventricular ejection fraction
(LVEF) < 40%) is assessed during preoperative evaluation in
untreated patients in stable condition, angiotensin-con-
verting enzyme (ACE) inhibitors are initiated as recom-
mended by the ESC guidelines on heart failure.22
Anaesthesia technique
During surgery, patients will receive standard of care
(hypnotics, opiates and muscle relaxant) in both groups to
provide optimal anaesthetic and surgical conditions.
Balanced anaesthesia should adequately control depth ofanaesthesia with minor intra-operative haemodynamic
changes.
Anaesthesia technique (intubation, mechanical ventila-
tion parameters, SaO2, end-tidal carbon dioxide partial
pressure) and all medication used during surgery will be
noted, including local or regional technique combined to
general anaesthesia and with special focus on anaesthesia
depth (Mean Alveolar Concentration, MAC), opiate
consumptions and duration of anaesthesia. Patients will
have standard postoperative pain management. BIS (bis-
pectral index) monitoring will be applied in all patients.
Haemodynamic monitoring
Perioperative haemodynamic monitoring will include
continuous measurement of hazard ratio (HR) and ischaemia
detection using 12-leadHoltermonitoring. Holtermonitoring
will start 12 h prior to surgery and continue during esmolol
infusion and after discontinuation of esmolol infusion for
a total of 72 h. Blood pressure will be measured continuously
during surgery and at least every 15 min for 48 h post-
operatively, depending on the haemodynamic condition of
the patient. After surgery, patients will be admitted to the
Intensive Care Unit, the Post Anaesthesia (High) Care Unit, or
the post-vascular surgery medium care unit for at least 24 h,
at the discretion of the attending anaesthesiologist and
vascular surgeon. All of these units can provide the level of
monitoring and care needed for the current study. Admission
to one of these units is customary in our centre after vascular
surgery. In patients with an LVEF <35%, additional haemo-
dynamic monitoring using a pulmonary artery catheter is
performed during surgery for goal-directed fluid and vaso-
active drug therapy, as per hospital protocol.
Haemodynamic management
Tachycardia will be managed with additional beta-blockers
only after excluding and treating underlying causes such as
320 E.J. Bakker et al.pain, bleeding, hypovolaemia and infection. If tachycardia is
likely to be induced by hypovolaemia, a fluid challenge will
be administered. If tachycardia does not resolve, it is
deemed not to be induced by hypovolaemia. Perioperative
bradycardia (HR< 40 bpm)will bemanagedwith intravenous
(i.v.) injection of atropine. Hypertension (>20% increase
from baseline systolic blood pressure) will be managed with
i.v. administration of standard care of vasodilating agent.
Hypotension (mean arterial pressure< 60mmHg) ismanaged
with fluids or vasopressor medication at the discretion of the
attending physician.
If heart rate is >80 bpm intra-operatively, a bolus of
0.25 mg kg1 of esmolol or placebo will be administered and
a 25 mcg kg1 min1 continuous infusion will be initiated. If
heart-rate control is not regained in 5 min, an additional
0.25mg kg1 bolus will be administered. Continuous infusion
will be titrated in steps of 25% of the current dose at 15-min
intervals to maintain a heart rate of 60e80 bpm with
a maximum of 300 mcg kg1 min1. If heart rate does not
exceed 80 bpm during surgery, the 25 mcg kg1 min1
continuous infusion of esmolol or placebo is initiated before
extubation without bolus infusion and titrated as described
earlier. The study drug will be withheld if systolic blood
pressure is below 100 mmHg.
If heart rate is outside the target window with no signs of
cardiac ischaemia detected by continuous electrocardio-
graphic monitoring, after providing the maximum dose of
study drug, no additional action will be taken. However, if
signs of cardiac ischaemia do not resolve rapidly with
uptitration of esmolol or placebo, rescue treatment with
i.v. injection of beta-blocker is provided according to good
clinical practice.
Outcome
Primary end point
The primary end point is total duration of heart rate outside
the target window presented in minutes. The target
window is defined as a heart rate between 60 and 80 bpm.
Secondary end points
The secondary study outcome for the efficacy of esmolol is
the occurrence of cardiac death and myocardial ischaemia,
defined as either transient electrocardiographic signs of
ischaemia or troponin T release or both, within 30 days of
surgery. In patients with tachycardia and ischaemia, the
prescription of rescue medication will be considered
a secondary study end point. Serial troponin T levels and
electrograph (ECG) recordings will be obtained prior to
surgery and on day 1, 3, 7 and 30.
Secondary outcome will also include other safety
parameters such as the occurrence of bradycardia (i.e.,
HR < 50 bpm) hypotension (SBP < 100) and transient
ischaemic attack (TIA) confirmed by neurologic examina-
tion or stroke as confirmed by neurologic examination and
computed tomography (CT) scan.
Sample-size calculation
Based on the results of the DECREASE III trial,27 the esti-
mated total length of heart rate outside the target window(60e80 bpm) in the control group will be 8.1  5.8 h. It is
anticipated that using esmolol, the total duration of heart
rate outside the target window will be reduced by 33%. This
estimation is based on the placebo-controlled study in 26
patients published by Raby et al.28 This means that a group
of 260 patients, 130 in each arm, is necessary to have
a power of 80% and an alpha of 0.05 to detect this differ-
ence. We expect that 10% of the population will be
excluded from the study based on the exclusion criteria.
Data analysis
Categorical data are described as numbers and percentages
and analyzed using the chi-square test. Continuous data are
expressed as medians with interquartile ranges (IQRs) and
compared using KruskaleWallis test. Logistic and Cox
regression analyses will used to evaluate the short- and
long-term prognosis of haemodynamic instability. In multi-
variate analysis, adjustments will be made for cardiac risk
factors, type of surgery and open or endovascular proce-
dure. Odds ratio and HRs are given with 95% confidence
intervals. For all tests, a p-value <0.05 (two-sided) is
considered significant. All analysis will be performed using
SPSS 17.0 statistical software (SPSS Inc., Chicago, IL, USA).
Discussion
This trial is primarily designed to assess the efficacy and
safety of perioperative esmolol infusion versus placebo as
an add-on to chronic low-dose beta-blocker use for heart-
rate control. Prevention of perioperative tachycardia
reduces perioperative cardiac ischaemia.28 Perioperative
ischaemia is related to cardiac adverse events and remains
an important cause of morbidity and mortality in patients
undergoing vascular surgery.3,4,7,11,12,29 For risk reduction,
a perioperative regimen consisting of beta-blockers and
a statin, both initiated at least a week prior to surgery, is
recommended in this population.19 Of note, the perioper-
ative period is characterised by haemodynamic fluctua-
tions. This warrants the use of a placebo and creates
a situation where it is difficult for the treating physician to
assess treatment allocation of an individual patient.
Randomised controlled trials that assessed the effect of
beta-blockers in the perioperative period reported diver-
gent results, as shown in Fig. 1. The DECREASE-I trial
observed a 10-fold reduction in the incidence of perioper-
ative death and MI in vascular surgery patients with evidence
of myocardial ischaemia on preoperative dobutamine stress-
echocardiography, treated with bisoprolol compared to
placebo.6 In a trial by Mangano, perioperative atenolol
therapy was not associated with an improved in-hospital
outcome; however, it was associated with a 50% reduction in
ECG evidence of myocardial ischaemia and significantly
lower mortality rates at 6 and 24 months after discharge.20
The Metoprolol after Vascular Surgery (MaVS), Peri-
Operative Beta-BLockadE (POBBLE) and DIabetic POst-
operative Mortality (DIPOM) trials did not find a significant
effect of perioperative metoprolol.30e32 All of these studies
included many low-risk patients, in contrast to the
DECREASE-I trial, which only included patients with induc-
ible ischaemia. In a retrospective cohort study of 782 969
Figure 1 Odds ratios (OR) of randomised beta-blocker trails
for perioperative myocardial infarction (MI) and cardiac death.
BBSA Z Beta Blocker in Spinal Anaesthesia; CI Z confidence
interval; DECREASE Z Dutch Echocardiographic Cardiac Risk
Evaluation Applying Stress Echocardiography; DIPOMZDiabetes
Postoperative Mortality and Morbidity; MaVSZMetoprolol after
Vascular Surgery; POBBLE Z PeriOperative Beta-BLockadE;
POISEZ PeriOperative Ischaemic Evaluation trial.
Figure 2 Odds ratios (OR) of randomised beta-blocker trails
for stroke, BBSA Z Beta Blocker in Spinal Anaesthesia;
CIZ confidence interval; DECREASEZDutch Echocardiographic
Cardiac Rick Evaluation Applying Stress Echocardiography;
DIPOM Z Diabetes Postoperative Mortality and Morbidity;
MaVS Z Metoprolol after Vascular Surgery; POBBLE Z
PeriOperative Beta-BlockadE; POISEZ PeriOperative Ischaemic
Evaluation trial.
DECREASE-XIII Trial Design 321patients undergoing major non-cardiac surgery, beta-
blocker use was associated with a significant beneficial
effect in high-risk patients but showed no effect or possible
harm in low-risk patients.33
The DECREASE-XIII trial will include only patients
undergoing major vascular surgery, including open lower
extremity arterial repair, open and endovascular abdominal
aortic repair and open carotid stenosis repair. These
patients are all at either intermediate or high-risk of
cardiac complications. Beta-blocker use in these patients
was previously demonstrated to be of benefit and is in
accordance with the 2009 ESC guidelines on perioperative
care.6,19,23
Studies by Raby28 and Feringa34 observed that higher
doses of beta-blockers and lower heart rates were associ-
ated with a marked reduction in the incidence of
ischaemia. These data suggest that early initiation of beta-
blocker therapy, monitoring of the heart rate and subse-
quent dose adjustment are of critical importance for the
likelihood that a patient will benefit from beta-blockade.
Controversy exists on the appropriate dosing regimen. In
the POISE study, patients were randomised for perioper-
ative metoprolol succinate or placebo. Metoprolol succi-
nate was initiated 2e4 h before surgery in a dose of 100 mg.
A second dose of 100 mg was administered if heart rate was
>80 and systolic blood pressure was >100 mmHg anytime
within the first 6 h after surgery. If this situation did not
occur, the second dose was administered 6 h after surgery,
if heart rate was 50 bpm or more and systolic blood pres-
sure was >100 mmHg. Then, a maintenance dose of 200 mg
of metoprolol succinate once daily was started 12 h after
the second gift for 30 days. Patients could receive up to
400 mg of metoprolol succinate on the first day of treat-
ment. The incidence of cardiac death, PMI and cardiac
arrest in patients randomised to metoprolol compared to
placebo was significantly reduced. However, this was offset
by an increased incidence of intra-operative hypotension,bradycardia and 30-day stroke and overall mortality in the
treatment group when compared to placebo, as shown in
Fig. 2.7,35,36 The hypothesis is that the frequently observed
ischaemic stroke was due to watershed infarction due to
hypotension and bradycardia in patients with a diseased
cerebrovascular tree.37,38 In the non-surgical setting, lower
starting doses are recommended, for instance, an initial
daily dose of 25e100 mg for hypertension, usually upti-
trated at weekly intervals.
Feringa et al. demonstrated that a 10 bpm increase in
both pre- and postoperative heart rate is associated with
a significantly increased risk of perioperative myocardial
ischaemia and cardiac troponin release and long-term
cardiac events and mortality (HR ranging from 1.4 to 2.6 per
10 bpm increase, p < 0.05 in all cases), after adjusting for
risk factors, medication use and preoperative cardiac stress
test results.34
Both bradycardia and increased heart rate are associated
with a significantly increased risk of cardiac complications.
These data support the importance of the maintenance of
tight heart-rate control as a primary end point.
A recent meta-analysis by Landoni et al. showed no
increase in the incidence of hypotension or bradycardia
during perioperative esmolol infusion. No data on the
incidence of stroke were reported in the trials included in
this meta-analysis.39
Titration of beta-blocker dose requires that treatment
be initiated optimally 30 days prior to surgery, or at least 1
week. Early initiation of beta-blocker therapy poses
a logistic difficulty in the United States, where patients are
commonly admitted to the hospital only on the day prior to
surgery. Perioperative esmolol infusion offers a possibility
for tight heart-rate control in this clinical condition,
although patients do not benefit from the additional car-
dioprotective anti-inflammatory effect of chronic beta-
blocker therapy.
322 E.J. Bakker et al.In conclusion, the optimal perioperative beta-blocker
dosing regimen is still controversial. Although proven to be
effective in the non-surgical setting in patients with heart
failure and CAD, safety issues such as hypotension and
bradycardia leading to stroke are potential deleterious
consequences. The use of low-dose regimens with careful
uptitration and intra-operative use of ultra-short-acting
beta-blockers might be the optimal treatment. A suffi-
ciently powered randomised clinical trial is warranted to
prove the safety and efficacy of these treatment regimens.
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